Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells
Tumor necrosis factor–related apoptosis inducing ligand (TRAIL) is considered to be a promising antitumor drug because of its selective proapoptotic properties on tumor cells. However, the clinical application of TRAIL is until now limited because of the resistance of several cancer cells, which can...
Main Authors: | Rita Setroikromo, Baojie Zhang, Carlos R. Reis, Rima H. Mistry, Wim J. Quax |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.00318/full |
Similar Items
-
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
by: Baojie Zhang, et al.
Published: (2019-05-01) -
The importance of controlled clinical trials with extracellular vesicles
by: Giovanni Camussi, et al.
Published: (2023-07-01) -
Trailing TRAIL Resistance: Novel Targets for TRAIL sensitization in Cancer cells
by: RACHANA eTRIVEDI, et al.
Published: (2015-04-01) -
Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
by: Changhong Ke, et al.
Published: (2020-05-01) -
DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL
by: Joaquín Marco-Brualla, et al.
Published: (2023-01-01)